Robinson, Brandi N.
Newman, Antoinette F.
Tefera, Eshetu
Herbolsheimer, Pia
Nunes, Raquel
Gallagher, Christopher
Randolph-Jackson, Pamela
Omogbehin, Adedamola
Dilawari, Asma
Pohlmann, Paula R. http://orcid.org/0000-0001-7914-5162
Mohebtash, Mahsa
Lee, Young
Ottaviano, Yvonne
Mohapatra, Avani
Lynce, Filipa
Brown, Richard
Mete, Mihriye
Swain, Sandra M. http://orcid.org/0000-0002-1320-3830
Article History
Received: 6 October 2016
Revised: 24 July 2017
Accepted: 3 August 2017
First Online: 18 September 2017
Competing interests
: P.H.’s institution received research funding from Genentech, Lilly, Pfizer, Wyeth, Amgen, and Merrimack. R.N. received travel from Caris Life Sciences. C.G. and A.D. have a consultant or advisory role with Genomic Health. P.R.P. has a leadership role and stock ownership with Immunonet BioSciences, a consulting or advisory role with Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, and patent No. US 20120201820. M.M. declares a consulting or advisory role with AstraZeneca and Bayer Compositions as Cancer Therapeutics. S.M.S. received honoraria from Roche, Clinigen Group, AstraZeneca, and Pfizer, has a consulting or advisory role with Genentech/Roche, Clinigen Group, OncoPlex Diagnostics, Lilly, and Pieris Pharmaceuticals, and received research Funding from Puma Biotechnology, Roche, Genentech, Pfizer, Merrimack, Lilly and received travel from Genentech/Roche. B.N.R., A.F.N., E.T., P.R.J., A.O., Y.L., Y.L.O., A.M., F.C.L., and M.M. declare that they have no competing financial interests.